A big company called Gilead Sciences makes medicine to help people who are sick. Some very rich people, called investors, want to bet money on whether the company's price will go up or down. They use a special way of betting called options. Today, some of these rich people made really big moves with their options, which could mean something important is going to happen soon. The last time we saw this, the company's price changed by about $5. Right now, some people think Gilead Sciences will do well and others don't. Some smart people called analysts think the company's price will be around $75 in a few months. Read from source...

1. The title is misleading: It implies that the options market has some special information about Gilead Sciences that cannot be obtained elsewhere. However, the article does not provide any evidence or explanation of how the options market reveals anything unique about the company's prospects or performance.
2. The article relies heavily on unverified and anonymous sources: Benzinga's options scanner is not a credible source of information, as it only reports unusual trading activity without providing any context or analysis of why these trades are significant or meaningful. Moreover, the identity of the investors remains unknown, which raises questions about their motives and credentials.
3. The article uses vague and ambiguous terms: For example, the phrase "something big is about to happen" implies that there is some imminent event or news that will affect Gilead Sciences' stock price, but the article does not specify what this event or news might be, nor how it would impact the company. Similarly, the terms "bullish" and "bearish" are subjective and relative, without clear criteria or definitions to support their use.
4. The article lacks any rigorous analysis of the options contracts: It merely describes the number and type of contracts, but does not examine their implications for the stock price, volatility, or risk-reward tradeoffs. For instance, it does not explain why there is a difference between puts and calls, or how these contracts relate to the underlying fundamentals of Gilead Sciences.
5. The article fails to provide any context or comparison for the options trading: It mentions that whales have been targeting a price range from $65.0 to $75.0, but does not compare this to other relevant factors such as the historical volatility of Gilead Sciences' stock, the prevailing market trends, or the industry benchmarks.
6. The article includes irrelevant and outdated information: For example, it mentions that the next earnings report is scheduled for 7 days from now, but this has no bearing on the current options trading activity or the company's prospects. Similarly, it cites an analyst's target price of $75.0, without considering whether this is reasonable or supported by any valuation metrics or forward-looking estimates.

Bearish
Reasoning: The article discusses the options market activity for Gilead Sciences, highlighting that there is a divided sentiment among heavyweight investors, with 50% leaning bullish and 50% bearish. Additionally, the price of GILD is down by -1.33%, reaching $66.04, which indicates a negative performance. The current RSI values also suggest that the stock may be oversold, further contributing to the overall bearish sentiment in the article.

To maximize profits from Gilead Sciences, I suggest the following strategies based on the options market data and analyst opinions. Please note that these are high-risk, high-reward scenarios and should only be pursued by experienced options traders who understand the potential consequences.